The company that reads blood flow through your arteries with math, not incisions - turning a routine CT scan into a personalized 3D model of the human heart.
Coronary artery disease is the single leading cause of death in the world. For decades, confirming it often meant an invasive procedure - a catheter threaded into the arteries to measure how badly a narrowing chokes off blood flow. Heartflow's premise, hatched in a computational-medicine lab in 2007, was that a good deal of that could be solved with mathematics instead.
The company takes a standard coronary CT angiogram - an image many patients already receive - and runs it through deep-learning algorithms and computational fluid dynamics, the same branch of physics used to model airflow over an aircraft wing. The output is a personalized, color-coded 3D model of a patient's coronary arteries, effectively a digital twin of that person's heart.
From that model, clinicians can see three things without touching the patient: where the arteries are narrowed (RoadMap Analysis), how much those narrowings actually restrict blood flow (FFRCT Analysis), and the type and volume of plaque lining the vessel walls (Plaque Analysis). Together they form the Heartflow One platform.
It is a quietly radical idea - that a well-modeled scan can stand in for a procedure - and the clinical establishment has come around to it. In 2021, Heartflow Analysis became the first AI-enabled technology written into the heart-disease guidelines of the American College of Cardiology and the American Heart Association.
"AI to turn coronary CTA images into personalized 3D models of the heart - actionable insight into plaque and blood flow, without the need for invasive procedures."
No catheter, no wire. Here is the path an image travels through Heartflow's cloud.
A hospital acquires a standard coronary CT angiogram and sends it to Heartflow's cloud.
Deep-learning algorithms build a personalized digital model of the coronary arteries.
Computational fluid dynamics simulates blood flow to calculate FFR at every point.
The cardiologist reviews color-coded flow, anatomy and plaque to plan treatment.
Calculates fractional flow reserve and pinpoints clinically significant coronary artery disease at every point in the major arteries - the commercial foundation, ~98% of revenue.
Automatically visualizes and quantifies the location and severity of narrowings for every acceptable CCTA, streamlining interpretation and revascularization strategy.
Delivers insight into plaque type, volume and distribution. The 2025 FDA-cleared platform adds an expanded nomogram and 3D color-coded visualization.
Heartflow has signaled a fourth analysis is expected to launch on the platform in the second quarter of 2026, extending its coronary care suite.
Charles Taylor and Christopher Zarins found Heartflow to apply computational modeling to coronary artery disease.
The non-invasive FFRCT Analysis earns regulatory clearances and enters clinical deployment.
Heartflow Analysis becomes the first AI-enabled technology named in national heart-disease guidelines; RoadMap and Plaque analyses launch.
The former Medtronic executive takes over as President and CEO to drive commercialization.
Heartflow surpasses a quarter-million patients assessed with FFRCT; Heartflow One unifies the products.
A new brand identity, Next-Gen Plaque Analysis, and a ~$364M IPO on the Nasdaq under HTFL.
Engineer and pioneer of computational medicine; co-founded Heartflow and later led the Center for Computational Medicine at UT Austin.
Vascular surgeon whose clinical perspective paired with Taylor's engineering to invent a new diagnostic category.
Former Medtronic cardiovascular leader; President and CEO steering commercialization and the 2025 public debut.
Cardiologists, radiologists, hospitals and imaging centers managing suspected CAD - across 1,500+ U.S. sites.
New analyses of 90,000+ patients show FFRCT Analysis delivers prognostic power and significant cost savings.
Plaque Analysis supported by ACC and AHA scientific statements for personalized management of suspected CAD.
Q3 results: revenue $46.3M, up 41% YoY; global cases up 48%; full-year guidance ~$173M.
FDA 510(k) clearance and launch of the Next-Generation Plaque Analysis platform with 3D color-coded visualization.
Completed an upsized Nasdaq IPO (HTFL), raising ~$364.2M gross at $19 per share.
Unveiled a new brand identity and a "bold new vision" for coronary artery disease management.
It uses AI and computational fluid dynamics to convert a standard coronary CT scan into a personalized 3D model of the heart, then analyzes blood flow (FFRCT), plaque and anatomy to help cardiologists diagnose and manage coronary artery disease without an invasive procedure.
Instead of threading a catheter into the arteries, Heartflow computes blood-flow significance from an existing CT scan. This non-invasive approach can help patients avoid unnecessary catheterizations while still identifying clinically significant narrowings.
Yes. Heartflow completed its IPO in August 2025 and trades on the Nasdaq under the ticker HTFL, raising about $364 million in gross proceeds.
Primarily through a pay-per-click model: it charges each time a physician reviews an FFRCT or Plaque Analysis. FFRCT Analysis accounted for roughly 98% of revenue as of Q3 2025.
Heartflow has been deployed at more than 1,500 U.S. hospitals and used to assess coronary artery disease in over 400,000 patients cumulatively.
Profile compiled from public sources including heartflow.com, Heartflow investor relations, SEC filings, the U.S. National Science Foundation, and industry press. Financial figures are approximate and include company guidance; the 2025 rebrand may differ visually from the logo shown. For the latest, see the official channels above.